ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 013

Applying Pathway Analysis to Whole Genome Data to Identify Pathophysiologic Pathways in Childhood-onset Systemic Lupus Erythematosus

Katie Heitzman1, Luis Franco2, Linda Hiraki3, Earl Silverman3, Christiaan Scott4, Ana Barrera-Vargas5, Zuoming Deng2, Mariana Kaplan2 and Laura Lewandowski2, 1NIH, Bethesda, MD, 2NIAMS, NIH, Bethesda, MD, 3The Hospital for Sick Children, Toronto, ON, Canada, 4University of Cape Town, South Africa, 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: genetics, genomics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, March 30, 2023

Title: Poster Breakout 1 - Lupus: Genetics, Epigenetics, & Social Determinants

Session Type: Breakout Session

Session Time: 5:10PM-5:40PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but twin/sibling high concordance rate suggests a genetic component triggered by stochastic environmental events. Childhood-onset SLE (cSLE) patients have an extreme phenotype, with early age of diagnosis and more severe disease relative to adult-onset SLE. Therefore, cSLE are an ideal population in which to study genetic contributors to disease. Historically, rare variant analyses have focused on a single gene shared by multiple patients in unrelated families. This approach does not consider that rare variants in people may cluster in genes that participate in similar biological processes. Therefore we aim to identify rare, enriched variants in genes of the same biological pathways that may contribute to the pathogenesis of SLE by applying pathway analysis to whole genome sequencing data of a diverse cSLE cohort.

Methods: SLE subjects met at least 4 of 11 revised American College of Rheumatology classification SLE criteria with disease onset prior to age 18. Whole blood samples collected from 81 subjects and 111 parents underwent whole genome sequencing (Table 1). Rare (minor allele frequency cutoff of 0.01), nonsynonymous variants in coding exons present in cSLE patients were selected, resulting in 483 variants in 232 genes. We restricted to variants present in 2 or more cSLE patients and not present in unaffected parents, or variants that were present more often in the cSLE patients than parental controls, assessed by Fisher’s exact test (p < 0.05). The resulting gene list was sorted into Gene Ontolgoy: Biological Processes (GO:BP) using Metascape. The Cytoscape Enrichment Map App (Cytoscape v. 3.7) was then used to generate a network of pathways enriched for genes in which cSLE patients harbored rare variants.

Results: Of the 483 unique rare exonic variants, 239 variants were sorted into 133 GO:BP genesets. (Table 2) Enrichment map analysis to clustered them into 18 biologic pathways including RNA processing and apoptosis. (Figure 1) Some pathways (e.g. nucleic acid regulation) are well-established causes of monogenic SLE, while others have not previously been described in the SLE.

Conclusion: Rare, exotic variants were enriched in biologic pathways in cSLE patients compared to parental controls. Pathway-network analysis is a useful approach to identify biological pathways and specific genes that could contribute to SLE risk. Ongoing analysis of the specific variants identified in each pathway will allow us to prioritize key genes and pathways for further study. Additionally, assessing clinical genotype/phenotype correlations could contribute to advancing SLE past a broad clinical phenotype to a more precise molecular diagnosis.

Supporting image 1Table 1. Demographic data for the cSLE cohort

Supporting image 2Figure 1. Biologic Pathways Eniched in Rare Coding Variants in cSLE patients. Each red circle is a geneset, represented as a node. The deeper the color of the node, the more the gene set is enriched in rare variants.

Supporting image 3Table 2. Comparison of number rare variants in coding regions between cSLE patients and unaffected parents.


Disclosures: K. Heitzman: None; L. Franco: None; L. Hiraki: None; E. Silverman: None; C. Scott: None; A. Barrera-Vargas: None; Z. Deng: None; M. Kaplan: None; L. Lewandowski: None.

To cite this abstract in AMA style:

Heitzman K, Franco L, Hiraki L, Silverman E, Scott C, Barrera-Vargas A, Deng Z, Kaplan M, Lewandowski L. Applying Pathway Analysis to Whole Genome Data to Identify Pathophysiologic Pathways in Childhood-onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/applying-pathway-analysis-to-whole-genome-data-to-identify-pathophysiologic-pathways-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/applying-pathway-analysis-to-whole-genome-data-to-identify-pathophysiologic-pathways-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology